Monoclonal Antibody Therapeutics

What Infusion Sites, Healthcare Providers, and Patients Need to Know

test

Monoclonal antibody therapeutics (mAb), including REGEN-COV and bamlanivimab/etesevimab can be used to treat eligible non-hospitalized patients who have tested positive for COVID-19 and have mild to moderate symptoms. These treatments mimic your immune system’s response to SARS-CoV-2 (the infection that causes COVID-19) and are available to eligible patients 12 years and older with a high risk of progressing to severe forms of COVID-19 or being hospitalized.

HHS/ASPR has purchased supplies of all COVID-19 monoclonal antibody therapeutic products and we are working with state and territorial health departments as well as national healthcare and medical organizations and associations to get the treatments into the hands of healthcare providers quickly, with a focus on areas of the country hardest hit by the pandemic.

​ Information for Infusion Sites Assessing your facility’s capabilities for becoming  an mAb site Ordering mAb therapeutics Seeking reimbursement and coverage REGEN-COV Bamlanivimab/etesevimab

​ Information for Healthcare Professionals Administering Monoclonal Antibody Treatments Information for Clinicians High-risk Patient Guidance Frequently Asked Questions Billing and Reimbursement Videos on mAB Therapies ​

​​ Information for Patients Understanding the benefits of mAb therapeutics Identifying who is eligible for mAb treatment Finding a treatment center Understanding Your COVID-19 Treatment Options (fact sheet)